• Shenzhen Third People’s Hospital, Shenzhen 518020, China;
HE Qing, Email: heqingjoe@163.com
Export PDF Favorites Scan Get Citation

Objective  To evaluate the effectiveness and safety of Gansu for chronic hepatitis B.
Methods  We searched The Cochrane Central Register of Controlled Trials (CCTR), PubMed, EMbase, CBM, CNKI, VIP, and Wanfang databases up to Dce. 2009. The methodological quality assessment and data extraction of the included studies were conducted by two reviewers independently according to the inclusion and exclusion criteria. Meta-analyses were performed for homogeneous studies using RevMan 4.2.10 software.
Results  A total of 14 studies involving 1 755 patients met the inclusion criteria. Of which, 12 studies did not report randomization method, and the other two studies reported inadequate methods of randomization. None of the studies enforced allocation concealment and performed blinding. We conducted subgroup analyses based on the outcome measures and interventions. The results of meta-analyses showed: (1) In terms of reducing ALT, Gansu + conventional therapy was superior to conventional therapy alone. (2) In terms of the HBsAg seroconversion rate, no significant difference was found between the two groups. (3) In terms of the HBeAg, no significant difference was found between the two groups at 3 months’ follow-up. (4) In terms of the HBV-DNA, Gansu + conventional therapy was superior to conventional therapy alone at 3 and 6 months’ follow-up, but theses differences were not found between Gansu + Lamivudine/ Adefovir and Lamivudine/ Adefovir alone. In terms of reducing the index of hepatic fibrosis, Gansu + conventional therapy was superior to conventional therapy alone.
Conclusion  Gansu might be effective in normalizing ALT levels, clearing HBV DNA, achieving virus seroconversion and improving hepatic fibrosis, without any serious adverse effects. However, because the overall effects cannot be pooled for analysis, more evidence is needed to support this finding.

Citation: TANG Qiyuan,HE Qing,BAI Bing,TANG Yimin,TANG Wei,AO Feijian. Gansu for Chronic Hepatitis B: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2010, 10(8): 978-984. doi: 10.7507/1672-2531.20100529 Copy

  • Previous Article

    Adefovir Versus Adefovir-Thymosin Alpha-1 Combination Therapy for Chronic Hepatitis B: A Systematic Review
  • Next Article

    Effectiveness and Safety of G-CSF for Acute Lymphoblastic Leukemia: A Systematic Review